Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X2RL
|
|||
| Former ID |
DNCL003810
|
|||
| Drug Name |
LY3012212
|
|||
| Synonyms |
Icrucumab
Click to Show/Hide
|
|||
| Indication | Arteriosclerosis [ICD-11: BD40] | Phase 2 | [1] | |
| Bladder cancer [ICD-11: 2C94] | Phase 2 | [1] | ||
| Company |
Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor receptor 1 (FLT-1) | Target Info | Modulator | [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| HIF-1 signaling pathway | ||||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Focal adhesion | ||||
| Transcriptional misregulation in cancer | ||||
| Rheumatoid arthritis | ||||
| Pathway Interaction Database | Glypican 1 network | |||
| HIF-2-alpha transcription factor network | ||||
| S1P3 pathway | ||||
| VEGF and VEGFR signaling network | ||||
| VEGFR1 specific signals | ||||
| Signaling events mediated by VEGFR1 and VEGFR2 | ||||
| Reactome | Neurophilin interactions with VEGF and VEGFR | |||
| VEGF binds to VEGFR leading to receptor dimerization | ||||
| WikiPathways | Focal Adhesion | |||
| Signaling by VEGF | ||||
| Angiogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024862) | |||
| REF 2 | Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32(2):303-11. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.